Nuclear Medicine and Biology
Volume 36, Issue 4 , Pages 427-433 , May 2009

The effect of PPAR-γ agonist on 18F-FDG uptake in tumor and macrophages and tumor cells

  • Se-Lim Kim

      Affiliations

    • Department of Nuclear Medicine, Chonbuk National University Medical School, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • Research Institute of Clinical Medicine, Chonbuk National University Medical School, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • Cyclotron Research Center, Chonbuk National University Hospital, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • ,
  • Eun-Mi Kim

      Affiliations

    • Department of Nuclear Medicine, Chonbuk National University Medical School, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • Research Institute of Clinical Medicine, Chonbuk National University Medical School, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • Cyclotron Research Center, Chonbuk National University Hospital, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • ,
  • Su-Jin Cheong

      Affiliations

    • Department of Nuclear Medicine, Chonbuk National University Medical School, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • Research Institute of Clinical Medicine, Chonbuk National University Medical School, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • Cyclotron Research Center, Chonbuk National University Hospital, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • ,
  • Chang-Moon Lee

      Affiliations

    • Department of Nuclear Medicine, Chonbuk National University Medical School, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • Research Institute of Clinical Medicine, Chonbuk National University Medical School, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • Cyclotron Research Center, Chonbuk National University Hospital, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • ,
  • Dong Wook Kim

      Affiliations

    • Department of Nuclear Medicine, Chonbuk National University Medical School, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • Research Institute of Clinical Medicine, Chonbuk National University Medical School, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • Cyclotron Research Center, Chonbuk National University Hospital, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • ,
  • Hwan-Jeong Jeong

      Affiliations

    • Department of Nuclear Medicine, Chonbuk National University Medical School, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • Research Institute of Clinical Medicine, Chonbuk National University Medical School, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • Cyclotron Research Center, Chonbuk National University Hospital, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • Corresponding Author InformationCorresponding author. Department of Nuclear Medicine, Chonbuk National University Hospital, Jeonju-si, Jeonbuk 561-712, Republic of Korea. Tel.: +82 63 250 1674; fax: +82 63 250 1676.
    • ,
  • Seok Tae Lim

      Affiliations

    • Department of Nuclear Medicine, Chonbuk National University Medical School, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • Research Institute of Clinical Medicine, Chonbuk National University Medical School, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • Cyclotron Research Center, Chonbuk National University Hospital, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • ,
  • Myung-Hee Sohn

      Affiliations

    • Department of Nuclear Medicine, Chonbuk National University Medical School, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • Research Institute of Clinical Medicine, Chonbuk National University Medical School, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • Cyclotron Research Center, Chonbuk National University Hospital, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • ,
  • Chang Yeol Yim

      Affiliations

    • Research Institute of Clinical Medicine, Chonbuk National University Medical School, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • Cyclotron Research Center, Chonbuk National University Hospital, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • Department of Internal Medicine, Chonbuk National University Medical School, Jeonju-si, Jeonbuk 561-712, Republic of Korea

Received 30 June 2008 ,Revised 4 December 2008 ,Accepted 15 January 2009.

References 

  1. Evans RM. The steroid and thyroid hormone receptor superfamily. Science. 1988;240:889–895
  2. Spiegelman BM, Flier JS. Adipogenesis and obesity: rounding out the big picture. Cell. 1996;87:377–389
  3. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med. 2004;351:1106–1118
  4. Berger JP, Petro AE, Macnaul KL, Kelly LJ, Zhang BB, Richards K, et al. Distinct properties and advantages of a novel peroxisome proliferator-activated receptor [gamma] selective modulator. Mol Endocrinol. 2003;17:662–676
  5. Serhan CN. Inflammation. Signaling the fat controller. Nature. 1996;384:23–24
  6. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology. 1996;137:354–366
  7. Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd Z, et al. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem. 1998;273:25573–25580
  8. Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res. 2000;49:497–505
  9. Clark RB, Bishop-Bailey D, Estrada-Hernandez T, Hla T, Puddington L, Padula SJ. The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J Immunol. 2000;164:1364–1371
  10. Faveeuw C, Fougeray S, Angeli V, Fontaine J, Chinetti G, Gosset P, et al. Peroxisome proliferator-activated receptor gamma activators inhibit interleukin-12 production in murine dendritic cells. FEBS Lett. 2000;486:261–266
  11. Gosset P, Charbonnier AS, Delerive P, Fontaine J, Staels B, Pestel J, et al. Peroxisome proliferator-activated receptor gamma activators affect the maturation of human monocyte-derived dendritic cells. Eur J Immunol. 2001;31:2857–2865
  12. Marx N, Sukhova G, Murphy C, Libby P, Plutzky J. Macrophages in human atheroma contain PPAR-gamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma (PPAR-gamma) expression and reduction of MMP-9 activity through PPAR-gamma activation in mononuclear phagocytes in vitro. Am J Pathol. 1998;153:17–23
  13. Yang XY, Wang LH, Chen T, Hodge DR, Resau JH, DaSilva L, et al. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonists. PPAR-gamma co-association with transcription factor NFAT. J Biol Chem. 2000;275:4541–4544
  14. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferators activated receptor-γ is a negative regulator of macrophages activation. Nature. 1998;391:79–82
  15. Jiang C, Ting AT, Seed B. PPAR-γ Agonists inhibit the production of monocyte inflammatory cytokines. Nature. 1998;391:82–86
  16. Flier JS, Mueckler MM, Usher P, Lodish HF. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science. 1987;235:1492–1495
  17. Tahara T, Ichiya Y, Kuwabara Y, Otsuka M, Miyake Y, Gunasekera R, et al. High [18F]- fluorodeoxyglucose uptake in abdominal abscesses: a PET study. J Comput Assist Tomogr. 1989;13:829–831
  18. Sasaki M, Ichiya Y, Kuwabara Y, Otsuka M, Tahara T, Fukumura T, et al. Ringlike uptake of [18F]FDG in brain abscess: a PET study. J Comput Assist Tomogr. 1990;14:486–487
  19. Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med. 1994;35:1647–1649
  20. Ichiya Y, Kuwabara Y, Sasaki M, Yoshida T, Akashi Y, Murayama S, et al. FDG-PET in infectious lesions: the detection and assessment of lesion activity. Ann Nucl Med. 1996;10:185–191
  21. Hanson MW, Glantz MJ, Hoffman JM, Friedman AH, Burger PC, Schold SC, et al. FDG-PET in the selection of brain lesions for biopsy. J Comput Assist Tomogr. 1991;15:796–801
  22. Meyer MA, Frey KA, Schwaiger M. Discordance between F-18 fluorodeoxyglucose uptake and contrast enhancement in a brain abscess. Clin Nucl Med. 1993;18:682–684
  23. Sugawara Y, Braun DK, Kison PV, Russo JE, Zasadny KR, Wahl RL. Rapid detection of human infections with fluorine-18 fluorodeoxyglucose and positron emission tomography: preliminary results. Eur J Nucl Med. 1998;25:1238–1243
  24. Sugawara Y, Gutowski TD, Fisher SJ, Brown RS, Wahl RL. Uptake of positron emission tomography tracers in experimental bacterial infections: a comparative biodistribution study of radiolabeled FDG, thymidine, l-methionine, 67Ga-citrate and 125I-HSA. Eur J Nucl Med. 1999;26:333–341
  25. Yamada S, Kubota K, Kubota R, Ido T, Tamahashi N. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med. 1995;36:1301–1306
  26. Toffoli G, Claudia C, Russo A, Gallo A, Bagnoli M, Boiocchi M. Overexpression of folate binding protein in ovarian cancers. Int J Cancer. 1997;74:193–197
  27. Mochizuki T, Tsukamoto E, Kuge Y, Kanegae K, Zhao S, Hikosaka K, et al. FDG Uptake and glucose transporter subtype expressions in experimental tumor and inflammation model. J Nucl Med. 2001;42:1551–1555
  28. Mellanen P, Minn H, Grénman R, Härkönen P. Expression of glucose transporters in head-and-neck tumors. Int J Cancer. 1994;56:622–629
  29. Marom EM, Aloia TA, Moore MB, Hara M, Herndon JE, Harpole DH, et al. Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer. Lung Cancer. 2001;33:99–107
  30. Higashi T, Tamaki N, Honda T, Torizuka T, Kimura T, Inokuma T, et al. Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. J Nucl Med. 1997;38:1337–1344
  31. Higashi T, Tamaki N, Torizuka T, Nakamoto Y, Sakahara H, Kimura T, et al. FDG Uptake, Glut-1 glucose transporter and cellularity in human pancreatic tumors. J Nucl Med. 1998;39:1727–1735
  32. Higashi K, Ueda Y, Sakurai A, Wang XM, Xu L, Murakami M, et al. Correlation of Glut-1 glucose transporter expression with [18F]FDG uptake in non-small cell lung cancer. Eur J Nucl Med. 2000;27:1778–1785
  33. Gu J, Yamamoto H, Fukunaga H, Danno K, Takemasa I, Ikeda M, et al. Correlation of GLUT-1 overexpression, tumor size, and depth of invasion with 18F-2-fluoro-2-deoxy-d-glucose uptake by positron emission tomography in colorectal cancer. Dig Dis Sci. 2006;51:2198–2205
  34. Tateishi U, Yamaguchi U, Seki K, Terauchi T, Arai Y, Hasegawa T. Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue sarcomas: a prospective evaluation by [18F]fluorodeoxyglucose positron emission tomography. Eur J Nucl Med Mol Imaging. 2006;33:683–691
  35. Tian M, Zhang H, Nakasone Y, Mogi K, Endo K. Expression of Glut-1 and Glut-3 in untreated oral squamous cell carcinoma compared with FDG accumulation in a PET study. Eur J Nucl Med Mol Imaging. 2004;31:5–12
  36. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med. 2002;43:1210–1217
  37. Buck AK, Halter G, Schirrmeister H, Kotzerke J, Wurziger I, Glatting G, et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med. 2003;44:1426–1431

☆ This study was supported by a grant from the National R&D Program for Cancer Control, Ministry of Health, Welfare and Family affairs, Republic of Korea (0620220) and Nuclear R&D program through KOSEF (M20702000003-08N0200-00310).

PII: S0969-8051(09)00035-3

doi: 10.1016/j.nucmedbio.2009.01.010

Nuclear Medicine and Biology
Volume 36, Issue 4 , Pages 427-433 , May 2009

Article Tools

* Image Usage & Resolution